Caroline L Ng

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1565594/publications.pdf

Version: 2024-02-01

18	1,098	516710 16	839539 18
papers	citations	h-index	g-index

19	19	19	1969
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria. Science Translational Medicine, 2015, 7, 296ra111.	12.4	254
2	Supergenomic Network Compression and the Discovery of EXP1 as a Glutathione Transferase Inhibited by Artesunate. Cell, 2014, 158, 916-928.	28.9	113
3	A potent antimalarial benzoxaborole targets a Plasmodium falciparum cleavage and polyadenylation specificity factor homologue. Nature Communications, 2017, 8, 14574.	12.8	110
4	Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study. Lancet Infectious Diseases, The, 2018, 18, 874-883.	9.1	106
5	Covalent Plasmodium falciparum-selective proteasome inhibitors exhibit a low propensity for generating resistance in vitro and synergize with multiple antimalarial agents. PLoS Pathogens, 2019, 15, e1007722.	4.7	58
6	Animal models for SARSâ€CoVâ€2 research: A comprehensive literature review. Transboundary and Emerging Diseases, 2021, 68, 1868-1885.	3.0	58
7	CRISPRâ€Cas9â€modified pfmdr1 protects Plasmodium falciparum asexual blood stages and gametocytes against a class of piperazineâ€containing compounds but potentiates artemisininâ€based combination therapy partner drugs. Molecular Microbiology, 2016, 101, 381-393.	2.5	56
8	Defining the Determinants of Specificity of Plasmodium Proteasome Inhibitors. Journal of the American Chemical Society, 2018, 140, 11424-11437.	13.7	54
9	Hexahydroquinolines are antimalarial candidates with potent blood-stage and transmission-blocking activity. Nature Microbiology, 2017, 2, 1403-1414.	13.3	47
10	Protein Degradation Systems as Antimalarial Therapeutic Targets. Trends in Parasitology, 2017, 33, 731-743.	3.3	46
11	Identification and Mechanistic Understanding of Dihydroorotate Dehydrogenase Point Mutations in Plasmodium falciparum that Confer in Vitro Resistance to the Clinical Candidate DSM265. ACS Infectious Diseases, 2019, 5, 90-101.	3.8	43
12	Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Doseâ€“Efficacy Modeling. PLoS Medicine, 2016, 13, e1002138.	8.4	35
13	Plasmodium falciparum Artemisinin Resistance: The Effect of Heme, Protein Damage, and Parasite Cell Stress Response. ACS Infectious Diseases, 2020, 6, 1599-1614.	3.8	34
14	Immuno-epidemiology and pathophysiology of coronavirus disease 2019 (COVID-19). Journal of Molecular Medicine, 2020, 98, 1369-1383.	3.9	30
15	Plasmodium falciparum In Vitro Drug Resistance Selections and Gene Editing. Methods in Molecular Biology, 2019, 2013, 123-140.	0.9	21
16	UV-triggered Affinity Capture Identifies Interactions between the Plasmodium falciparum Multidrug Resistance Protein 1 (PfMDR1) and Antimalarial Agents in Live Parasitized Cells. Journal of Biological Chemistry, 2013, 288, 22576-22583.	3.4	18
17	Repurposing Quinoline and Artemisinin Antimalarials as Therapeutics for SARS-CoV-2: Rationale and Implications. ACS Pharmacology and Translational Science, 2021, 4, 613-623.	4.9	9
18	A Proteasome Mutation Sensitizes P.Âfalciparum Cam3.II K13^{C580Y} Parasites to DHA and OZ439. ACS Infectious Diseases, 2021, 7, 1923-1931.	3.8	6